Mankind Pharma has reserved not more than 50% shares of the offer for qualified institutional buyers.
#2 Financial position During the pandemic, the pharma company's revenue was hit which should come as a surprise because pharma stocks boomed and were the biggest gainers of the Covid-19 rally.
#4 Arguments in favor of the business The company is in a very niche segment with strong visibility in the API, formulations, and consumer health segment.
If Mankind Pharma fails to comply with the applicable regulations prescribed by the governments and the relevant regulatory agencies, its business, financial condition, cash flows, and results of operations will be adversely affected.
Any disruption, slowdown, or shutdown in its manufacturing or R&D operations could adversely affect the business.
Source: NDTV